Health and Me

Dr Gaurav Kharya

Can India Build The Next Generation Of CAR-T Therapies?

India’s cell and gene therapy ecosystem is beginning to attract a different kind of attention that is driven not just by healthcare demand, but by proprietary science and platform-led innovation.

For investors, however, the larger story may not be the funding round itself. It may be the problem the company is trying to solve.

CAR-T therapies have transformed outcomes for several difficult-to-treat blood <a href="https://www.healthandme.com/health/cancer">cancer</a>s globally. But despite strong initial responses, relapse remains one of the field’s biggest limitations. One reason is antigen escape, which means cancer cells can change the markers that therapies use to identify them, making them harder to detect over time.

In an analysis of 4,129 CAR-T treated patients, relapse remained a substantial issue after single-target therapy, with 42.1% of relapses associated with loss of the CD19 target itself. The finding points to a larger issue: precision may not be enough if therapies lose visibility over time.

The response increasingly appears to be a move toward multi-target and more durable platforms. A bispecific CAR-T platform designed to recognize more than one tumor marker, to reduce relapse is crucial.

The science itself is becoming increasingly platform-oriented. Beyond broader targeting, recent work explored why immune cells themselves lose effectiveness over time and identified pathways associated with stronger persistence and memory. While still early, the broader implication is that future therapies may need to be designed not only to attack disease, but also to remain active longer.

For India, that creates a larger opportunity. Historically, advanced therapies such as CAR-T have remained expensive and heavily dependent on technologies developed elsewhere. The aim is to significantly reduce treatment costs while building indigenous capabilities across design and manufacturing.

The shift matters because biotech investing is increasingly moving beyond services and generics toward intellectual property and platform science. The transition from bedside observations to translational platforms may be where the next phase of healthcare innovation and investment gets built.

Health Conditions A-Z

health

can-india-build-the-next-generation-of-car-t-therapies

india

CAR T cell therapy for cancer

car t cell therapy

Cancer

cell therapy

gene therapy

sugar

Natural VS Processed: Expert Decodes The Impact Of Sugar On Your Body

us-surgeon-general-issues-advisory-to-limit-childrens-screen-time

US Surgeon General Issues Advisory To Limit Children's Screen Time

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

India’s cell and gene therapy ecosystem is beginning to attract a different kind of attention that is driven not just by healthcare demand, but by proprietary science and platform-led innovation. For investors, however, the larger story may not be the funding round itself. It may be the problem the company is trying to solve.CAR-T therapies have transformed outcomes for several difficult-to-treat blood cancers globally. But despite strong initial responses, relapse remains one of the field’s biggest limitations. One reason is antigen escape, which means cancer cells can change the markers that therapies use to identify them, making them harder to detect over time.In an analysis of 4,129 CAR-T treated patients, relapse remained a substantial issue after single-target therapy, with 42.1% of relapses associated with loss of the CD19 target itself. The finding points to a larger issue: precision may not be enough if therapies lose visibility over time.The response increasingly appears to be a move toward multi-target and more durable platforms. A bispecific CAR-T platform designed to recognize more than one tumor marker, to reduce relapse is crucial.The science itself is becoming increasingly platform-oriented. Beyond broader targeting, recent work explored why immune cells themselves lose effectiveness over time and identified pathways associated with stronger persistence and memory. While still early, the broader implication is that future therapies may need to be designed not only to attack disease, but also to remain active longer.For India, that creates a larger opportunity. Historically, advanced therapies such as CAR-T have remained expensive and heavily dependent on technologies developed elsewhere. The aim is to significantly reduce treatment costs while building indigenous capabilities across design and manufacturing.The shift matters because biotech investing is increasingly moving beyond services and generics toward intellectual property and platform science. The transition from bedside observations to translational platforms may be where the next phase of healthcare innovation and investment gets built.

can india build the next generation of car-t therapies?

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Can India Build The Next Generation Of CAR-T Therapies?

Can Running Marathons Or Ultramarathons Raise Colon Cancer Risk? Study Sparks Concern

Bruce Willis Has Become More ‘Tender’ Amid Dementia Battle, Says Daughter

India Cracks Down On Injectable Cosmetic Procedures In Beauty Clinics

Health Conditions A-Z

Can India Build The Next Generation Of CAR-T Therapies?

Natural VS Processed: Expert Decodes The Impact Of Sugar On Your Body

US Surgeon General Issues Advisory To Limit Children's Screen Time